{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:10:00Z","timestamp":1776406200623,"version":"3.51.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00228-026-04015-9","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:43:17Z","timestamp":1773222197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic evaluation of sodium-glucose transporter 2 inhibitors compared with glucagon-like peptide 1 receptor agonist for the treatment of type 2 diabetes: a systematic review"],"prefix":"10.1007","volume":"82","author":[{"given":"Lu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinglin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"1","key":"4015_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"MAB Khan","year":"2020","unstructured":"Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J (2020) Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health 10(1):107\u2013111","journal-title":"J Epidemiol Glob Health"},{"key":"4015_CR2","unstructured":"Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet]. 10th edition. Brussels: International Diabetes Federation; 2021. Table 3.1, Estimated total number of adults (20\u201379 years) with diabetes in 2021, 2030 and 2045. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK581940\/table\/ch3.t1\/"},{"issue":"12","key":"4015_CR3","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s00125-021-05571-8","volume":"64","author":"A Green","year":"2021","unstructured":"Green A, Hede SM, Patterson CC, Wild SH, Imperatore G, Roglic G, Beran D (2021) Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia 64(12):2741\u20132750","journal-title":"Diabetologia"},{"issue":"6","key":"4015_CR4","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s13300-021-01060-8","volume":"12","author":"E Artime","year":"2021","unstructured":"Artime E, Romera I, Diaz-Cerezo S, Delgado E (2021) Epidemiology and economic burden of cardiovascular disease in patients with type 2 diabetes mellitus in Spain: a systematic review. Diabetes Ther 12(6):1631\u20131659","journal-title":"Diabetes Ther"},{"issue":"2","key":"4015_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s13300-023-01503-4","volume":"15","author":"A Perez","year":"2024","unstructured":"Perez A, Redondo-Anton J, Romera I, Lizan L, Rubio-de Santos M, Diaz-Cerezo S et al (2024) Disease and Economic Burden of Poor Metabolic and Weight Control in Type 2 Diabetes in Spain: A Systematic Literature Review. Diabetes Ther 15(2):325\u2013341","journal-title":"Diabetes Ther"},{"issue":"1","key":"4015_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.22270\/jddt.v15i1.6914","volume":"15","author":"V Kumar","year":"2025","unstructured":"Kumar V, Amulya VB, Sharma M, Saikrupa BV (2025) Combination therapy of SGLT 2 inhibitors and GLP 1 receptor agonists for glycaemic management through weight reduction. J Drug Deliv Ther 15(1):142\u2013148","journal-title":"J Drug Deliv Ther"},{"issue":"4","key":"4015_CR7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/dom.14625","volume":"24","author":"OS Reifsnider","year":"2022","unstructured":"Reifsnider OS, Pimple P, Brand S, Bergrath Washington E, Shetty S, Desai NR (2022) Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States. Diabetes Obes Metab 24(4):652\u2013661","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"4015_CR8","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65(12):1925\u20131966","journal-title":"Diabetologia"},{"issue":"31","key":"4015_CR9","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1093\/eurheartj\/ehab530","volume":"43","author":"K Oyama","year":"2022","unstructured":"Oyama K, Raz I, Cahn A, Kuder J, Murphy SA, Bhatt DL et al (2022) Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Eur Heart J 43(31):2958\u20132967","journal-title":"Eur Heart J"},{"issue":"22","key":"4015_CR10","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128","journal-title":"N Engl J Med"},{"issue":"3","key":"4015_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031586","volume":"13","author":"A Sharma","year":"2024","unstructured":"Sharma A, Razaghizad A, Joury A, Levin A, Bajaj HS, Mancini GBJ et al (2024) Primary and secondary cardiovascular and kidney prevention with canagliflozin: insights from the CANVAS program and CREDENCE trial. J Am Heart Assoc 13(3):e031586","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"4015_CR12","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1172\/JCI78371","volume":"124","author":"LL Baggio","year":"2014","unstructured":"Baggio LL, Drucker DJ (2014) Glucagon-like peptide-1 receptors in the brain: controlling foo intake and body weight. J Clin Invest 124(10):4223\u20134226","journal-title":"J Clin Invest"},{"key":"4015_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116471","volume":"229","author":"Z Ke","year":"2024","unstructured":"Ke Z, Ma Q, Ye X, Wang Y, Jin Y, Zhao X et al (2024) Peptide GLP-1 receptor agonists: From injection to oral delivery strategies. Biochem Pharmacol 229:116471","journal-title":"Biochem Pharmacol"},{"issue":"372","key":"4015_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29(372):n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4015_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, James T, Marcello M (2010) A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy 6:5\u20139. https:\/\/doi.org\/10.1332\/174426410X482999","journal-title":"Evid Policy"},{"key":"4015_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S et al (2013) Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health 16:231\u2013250","journal-title":"Value Health"},{"issue":"2","key":"4015_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40256-022-00564-3","volume":"23","author":"A Rezapour","year":"2023","unstructured":"Rezapour A, Tashakori-Miyanroudi M, Haghjoo M, Barzegar M, Tatarpour P, Souresrafil A, Gorji HA, Yousefzadeh N, Sheikhy-Chaman M (2023) Cost effectiveness of adding dapagliflozin to standard care in heart failure patients with reduced ejection fraction: a systematic review. Am J Cardiovasc Drugs 23(2):127\u2013144","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"4015_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s41669-023-00416-z","volume":"7","author":"R Pulleyblank","year":"2023","unstructured":"Pulleyblank R, Larsen NB (2023) Cost-effectiveness of semaglutide vs. empagliflozin, canagliflozin, and sitagliptin for treatment of patients with type 2 diabetes in Denmark: a decision-analytic modelling study. Pharmacoeconomics 7(4):579\u2013591","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"4015_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2217\/cer-2021-0169","volume":"11","author":"LH Ehlers","year":"2021","unstructured":"Ehlers LH, Lamotte M, Ramos MC, Sandgaard S, Holmgaard P, Frary EC, Ejskjaer N (2021) The cost\u2013effectiveness of oral semaglutide versus empagliflozin in type 2 diabetes in Denmark. J Comp Eff Res 11(1):29\u201337","journal-title":"J Comp Eff Res"},{"issue":"1","key":"4015_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13300-019-00736-6","volume":"11","author":"SC Bain","year":"2020","unstructured":"Bain SC, Hansen BB, Malkin SJP, Nuhoho S, Valentine WJ, Chubb B et al (2020) Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. Diabetes Ther 11(1):259\u2013277","journal-title":"Diabetes Ther"},{"issue":"9","key":"4015_CR21","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s13300-020-00883-1","volume":"11","author":"M Ramos","year":"2020","unstructured":"Ramos M, Cummings MH, Ustyugova A, Raza SI, de Silva SU, Lamotte M (2020) Long-term cost-effectiveness analyses of empagliflozin versus oral semaglutide, in addition to metformin, for the treatment of type 2 diabetes in the UK. Diabetes Ther 11(9):2041\u20132055","journal-title":"Diabetes Ther"},{"issue":"3","key":"4015_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s41669-021-00317-z","volume":"6","author":"B Eliasson","year":"2022","unstructured":"Eliasson B, Ericsson A, Fridhammar A, Nilsson A, Persson S, Chubb B (2022) Long-term cost effectiveness of oral semaglutide versus empagliflozin and sitagliptin for the treatment of type 2 diabetes in the Swedish setting. Pharmacoecon Open 6(3):343\u2013354","journal-title":"Pharmacoecon Open"},{"issue":"7","key":"4015_CR23","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1007\/s12325-022-02156-8","volume":"39","author":"J Franch-Nadal","year":"2022","unstructured":"Franch-Nadal J, Malkin SJP, Hunt B, Martin V, Gallego Estebanez M, Vidal J (2022) The cost-effectiveness of oral semaglutide in Spain: a long-term health economic analysis based on the PIONEER clinical trials. Adv Ther 39(7):3180\u20133198","journal-title":"Adv Ther"},{"issue":"1","key":"4015_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13098-022-00801-4","volume":"14","author":"SJP Malkin","year":"2022","unstructured":"Malkin SJP, Carvalho D, Costa C, Conde V, Hunt B (2022) The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. Diabetol Metab Syndr 14(1):32","journal-title":"Diabetol Metab Syndr"},{"key":"4015_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108759","volume":"175","author":"SJP Malkin","year":"2021","unstructured":"Malkin SJP, Hunt B, Huisman EL, Grand TS, Chubb B (2021) The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials. Diabetes Res Clin Pract 175:108759","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"4015_CR26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2217\/cer-2020-0071","volume":"9","author":"M Ramos","year":"2020","unstructured":"Ramos M, Ustyugova A, Hau N, Lamotte M (2020) Cost\u2013effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in type II diabetes. J Comp Eff Res 9(11):781\u2013794","journal-title":"J Comp Eff Res"},{"issue":"1","key":"4015_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12962-021-00299-z","volume":"19","author":"M Ramos","year":"2021","unstructured":"Ramos M, Men P, Wang X, Ustyugova A, Lamotte M (2021) Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost Eff Resour Alloc 19(1):46","journal-title":"Cost Eff Resour Alloc"},{"issue":"5","key":"4015_CR28","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s13300-021-01040-y","volume":"12","author":"LH Ehlers","year":"2021","unstructured":"Ehlers LH, Lamotte M, Monteiro S, Sandgaard S, Holmgaard P, Frary EC et al (2021) The cost-effectiveness of empagliflozin versus liraglutide treatment in people with type 2 diabetes and established cardiovascular disease. Diabetes Ther 12(5):1523\u20131534","journal-title":"Diabetes Ther"},{"issue":"3","key":"4015_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s13300-022-01221-3","volume":"13","author":"LH Ehlers","year":"2022","unstructured":"Ehlers LH, Lamotte M, Ramos MC, Sandgaard S, Holmgaard P, Kristensen MM et al (2022) The cost-effectiveness of subcutaneous semaglutide versus empagliflozin in type 2 diabetes uncontrolled on metformin alone in Denmark. Diabetes Ther 13(3):489\u2013503","journal-title":"Diabetes Ther"},{"issue":"15","key":"4015_CR30","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2217\/cer-2021-0016","volume":"10","author":"MF Zupa","year":"2021","unstructured":"Zupa MF, Codario RA, Smith KJ (2021) Cost\u2013effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for type 2 diabetes. J Comp Eff Res 10(15):1133\u20131141","journal-title":"J Comp Eff Res"},{"issue":"2","key":"4015_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s13300-020-00989-6","volume":"12","author":"M Capehorn","year":"2021","unstructured":"Capehorn M, Hallen N, Baker-Knight J, Glah D, Hunt B (2021) Evaluating the cost-effectiveness of once-weekly semaglutide 1 mg versus empagliflozin 25 mg for treatment of patients with type 2 diabetes in the UK setting. Diabetes Ther 12(2):537\u2013555","journal-title":"Diabetes Ther"},{"issue":"2","key":"4015_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13696998.2019.1681436","volume":"23","author":"JJ Gorgojo-Martinez","year":"2020","unstructured":"Gorgojo-Martinez JJ, Malkin SJP, Martin V, Hallen N, Hunt B (2020) Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. J Med Econ 23(2):193\u2013203","journal-title":"J Med Econ"},{"issue":"4","key":"4015_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40258-022-00726-z","volume":"20","author":"S Stafford","year":"2022","unstructured":"Stafford S, Bech PG, Fridhammar A, Miresashvili N, Nilsson A, Willis M et al (2022) Cost-effectiveness of once-weekly semaglutide 1 mg versus canagliflozin 300 mg in patients with type 2 diabetes mellitus in a Canadian setting. Appl Health Econ Health Policy 20(4):543\u2013555","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"4015_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s13300-017-0250-y","volume":"8","author":"G Vega-Hernandez","year":"2017","unstructured":"Vega-Hernandez G, Wojcik R, Schlueter M (2017) Cost-effectiveness of liraglutide versus dapagliflozin for the treatment of patients with type 2 diabetes mellitus in the UK. Diabetes Ther 8(3):513\u2013530","journal-title":"Diabetes Ther"},{"key":"4015_CR35","unstructured":"Liu GG, et al (2020) China guidelines for pharmacoeconomic evaluations (2020 edn). In: Jin BD, Xu H, (eds). Chapter 3 Cost. Beijing; 2020, pp 167\u2013167"},{"issue":"1","key":"4015_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1080\/13696998.2023.2240957","volume":"26","author":"S Berry","year":"2023","unstructured":"Berry S, Chubb B, Acs A, Falla E, Verma A, Malkin SJP et al (2023) Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide. J Med Econ 26(1):1019\u20131031","journal-title":"J Med Econ"},{"key":"4015_CR37","unstructured":"Strohmaier C, Zechmeister-Koss I (2024) Threshold values in health economic evaluations and decision-making. HTA-Projektbericht 163. https:\/\/eprints.aihta.at\/1549\/"},{"key":"4015_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-11-22","volume":"11","author":"T Shiroiwa","year":"2013","unstructured":"Shiroiwa T, Igarashi A, Fukuda T, Ikeda S (2013) WTP for a QALY and health states: more money for severer health states? Cost Eff Resour Alloc 11:22","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"4015_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-013070","volume":"9","author":"L Xu","year":"2024","unstructured":"Xu L, Chen M, Angell B, Jiang Y, Howard K, Jan S, Si L (2024) Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year. BMJ Glob Health 9(1):e013070","journal-title":"BMJ Glob Health"},{"key":"4015_CR40","doi-asserted-by":"crossref","unstructured":"Davies MJ, et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45(11):2753\u201386","DOI":"10.2337\/dci22-0034"},{"issue":"1","key":"4015_CR41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2478\/acph-2022-0011","volume":"72","author":"S Zerovnik","year":"2021","unstructured":"Zerovnik S, Kos M, Locatelli I (2021) Initiation of insulin therapy in patients with type 2 diabetes: an observational study. Acta Pharm 72(1):147\u2013157","journal-title":"Acta Pharm"},{"issue":"1","key":"4015_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","volume":"22","author":"M Sittimart","year":"2024","unstructured":"Sittimart M, Rattanavipapong W, Mirelman AJ et al (2024) An overview of the perspectives used in health economic evaluations. Cost Eff Resour Alloc 22(1):41","journal-title":"Cost Eff Resour Alloc"},{"issue":"10","key":"4015_CR43","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","volume":"38","author":"DD Kim","year":"2020","unstructured":"Kim DD, Silver MC, Kunst N et al (2020) Perspective and costing in cost-effectiveness analysis, 1974\u20132018. Pharmacoeconomics 38(10):1135\u20131145","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"4015_CR44","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A et al (2016) Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA 316(10):1093\u20131103","journal-title":"JAMA"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04015-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04015-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04015-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:37:32Z","timestamp":1776404252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04015-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4015"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04015-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}